CION Ameerpet
Being told that chemotherapy comes first and surgery later can sound like the order has been reversed, or that something has quietly been given up on. It is neither. In advanced ovarian cancer, shrinking the disease before operating is a deliberate, head-to-head-tested route, chosen because it gives the operation a far better chance of removing everything that can be seen.
If you have been searching neoadjuvant chemotherapy ovarian cancer since the appointment, you are probably trying to answer one question: does chemotherapy first mean my cancer is worse? It does not. Neoadjuvant simply means before surgery. The other route — operating first, chemotherapy afterwards — is called primary debulking. Both use the same two treatments. What changes is the order.
The order is decided by one thing above all: whether a surgeon could remove every visible deposit of disease today. That is the target, and it is called complete cytoreduction. Ovarian cancer spreads across the surface of the abdomen rather than as a single lump, so disease can sit on the diaphragm, on the liver surface, in the mesentery of the small bowel or around major vessels. Where the CT scan shows that pattern, operating immediately usually ends with disease left behind — a long operation, an incomplete result, and chemotherapy delayed by weeks of recovery. Giving chemotherapy first shrinks and softens the disease so the same operation can achieve what it is meant to achieve.
The sequence most women follow is three to four cycles of platinum-based chemotherapy for ovarian cancer, a response assessment, then interval debulking surgery, then the remaining cycles, and finally maintenance therapy chosen from BRCA and HRD results. Written out like that, it is a plan with a beginning, a middle and an end — which is usually the reassuring part, because a plan of this shape is not what anyone offers when they have run out of options.
Chemotherapy given first, to shrink disease that could not all be removed today. Often abbreviated NACT. In ovarian cancer it is a standard route for advanced disease, not an experimental one.
The cytoreductive operation performed between cycles of chemotherapy, usually after the third or fourth. It is called interval because it sits inside the chemotherapy course rather than before it.
The cycles that follow the operation and complete the planned course. The total number of cycles is broadly the same whichever order is used; only the position of the surgery moves.
Two randomised trials — EORTC 55971 and the UK CHORUS trial — compared operating first against giving chemotherapy first in advanced ovarian cancer. Both found that neoadjuvant chemotherapy followed by interval debulking produced survival no worse than primary debulking surgery, while causing fewer serious surgical complications and fewer deaths around the time of the operation. That is why chemotherapy first became a recognised standard route rather than a compromise: it was tested head-to-head against the alternative, and it held up. Source: Vergote I et al., New England Journal of Medicine (2010); Kehoe S et al., The Lancet (2015); NCCN Ovarian Cancer guidelines.
No single finding decides this. A tumour board weighs the whole picture, and the honest summary is that the route is chosen to give complete removal the best chance — whenever that happens to be achievable.
| What is being weighed | Points towards surgery first | Points towards chemotherapy first |
|---|---|---|
| Where the disease sits on CT | Confined to sites a specialist surgeon could clear completely in one operation. | Deposits on the diaphragm or liver surface, in the mesentery of the small bowel or around major vessels, that could not all be removed safely today. |
| Stage | Stage 3 disease that reads as completely resectable. | Stage 4 disease, with fluid around a lung or spread beyond the abdomen. |
| Ascites and pleural fluid | Little or no free fluid. | Large-volume ascites, or a pleural effusion causing breathlessness. |
| Fitness for a long operation | Well enough for major surgery and a prompt recovery. | Frailty, malnutrition, significant heart or lung disease, or poor performance status. |
| Tissue diagnosis | Confirmed on the specimen removed at the operation itself. | Needed before chemotherapy can start — from an image-guided biopsy or fluid cytology. |
| Who decides | A tumour board, with the gynaecologic-oncology surgeon in the room. | The same board — and where imaging leaves it genuinely uncertain, a diagnostic laparoscopy settles it. |
*Where imaging sits on the fence, a short laparoscopic look is often more honest than another scan. It answers the resectability question directly instead of inferring it.
Most women want to know two things: what happens next, and roughly when. This is the sequence in the order you will live through it.
Chemotherapy cannot be started on a scan alone. Proof is needed, and it comes from an image-guided biopsy of an accessible deposit, or from cells in drained ascitic or pleural fluid. This also identifies the subtype, which matters because not every ovarian cancer responds to platinum-based treatment in the same way. It is the step people find most frustrating, because it can add a week — and it is the step that stops the wrong treatment being given confidently.
A CT of the chest, abdomen and pelvis maps every site and becomes the baseline that later scans are measured against. Baseline CA-125, blood counts, kidney and liver function, a nutrition review and a performance-status assessment complete the picture. Where ascites is causing real discomfort or breathlessness, draining it before the first cycle is reasonable and usually brings quick relief.
Given as a day-unit infusion, most often every three weeks, so three cycles occupy roughly nine weeks. Response is often felt before it is measured: the abdomen softens, appetite returns, breathing eases as ascites reabsorbs. Side effects are managed actively rather than endured — there is more on what to expect in our guide to chemotherapy for ovarian cancer.
After the third cycle, a repeat CT is compared with the baseline scan, alongside the CA-125 trend and an examination. The question is narrow and practical: could a surgeon now remove all visible disease? In most women the answer is yes and the operation is booked. Where the answer is not yet, chemotherapy continues and the question is asked again rather than abandoned.
Usually four to six weeks after the last cycle, once blood counts have recovered. The aim is complete cytoreduction — nothing visible left at the end. CION coordinates this operation with specialist gynaecologic-oncology surgeons at partner centres, where it is performed and may be billed. We say that plainly rather than let it be discovered on an invoice, and we arrange it that way because who operates genuinely affects how completely disease is removed.
Chemotherapy resumes once the wound has healed, usually around three to four weeks after the operation, to complete the planned course. BRCA and HRD results — ideally sent early rather than at the end — then guide whether maintenance therapy of the PARP-inhibitor or anti-angiogenic class is offered. Chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing are delivered in-house at CION across 35+ centres.
*Timings are typical rather than promised. Delays for blood counts, infection or nutrition are common and are not a sign that the plan is failing.
None of these means the treatment is not working. Each is a reason to ring the chemotherapy unit the same day rather than wait for the next cycle — which is exactly why you are given a 24-hour number.
Treat this as an emergency, day or night. Infection during a low blood count needs antibiotics within the hour, not an appointment next week.
Colicky pain and a distending abdomen can mean bowel obstruction. It needs assessment the same day rather than laxatives at home.
Could be a clot, or fluid collecting around a lung. Both are treatable, and both are worse for being left over a weekend.
Persistent vomiting or diarrhoea dehydrates quickly during chemotherapy and affects the kidneys. Ring before you stop passing much urine.
Nerve effects in the hands and feet are dose-related. Reported early, doses can be adjusted; ignored, the change can become long-lasting.
Ascites returning fast between cycles is worth a scan rather than a wait, as it may change the timing of the response assessment.
Keep the unit’s number saved in your phone, and tell whoever is at home with you where it is. Most of these calls end in reassurance — and the few that do not are exactly the ones that needed making.
Bring your CT report, your biopsy or cytology result and your CA-125 values. In 45 minutes a medical oncologist can explain why chemotherapy was placed first, what the response assessment will look for, and when the surgical window is expected to open.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If your current plan is the right one, we will say so plainly rather than manufacture a reason to change it.
The operation in the middle of chemotherapy is the part people know least about, and the part that most influences what the whole treatment achieves.
Surgeons describe the result of a debulking operation by what remains at the end. Complete cytoreduction, often written R0, means no visible disease. Small-volume residual disease is R1. This distinction is not surgical vanity: outcomes are consistently better when nothing visible remains, and that single objective explains almost every decision made about the timing and the extent of the operation.
It is also why chemotherapy is sometimes given first. An operation that ends with deposits still in place has taken a great deal from you and delivered less than it should. Shrinking the disease beforehand protects the value of the operation rather than postponing it.
The standard operation removes both ovaries and fallopian tubes, the uterus and cervix, and the omentum — the apron of fatty tissue over the bowel where ovarian cancer very commonly settles. Involved peritoneum is stripped, and lymph nodes are removed where they look or feel abnormal.
Where disease demands it, the operation can extend to removing a segment of bowel, stripping the diaphragm, or removing the spleen. Your surgeon should tell you beforehand which of these is likely in your case, and whether a temporary stoma is a possibility, so that nothing is a surprise afterwards. Our guide to debulking surgery goes through each part in more detail.
This is worth asking about directly. Complete removal is more often achieved when the operation is done by a surgeon trained in gynaecologic oncology, in a centre that performs these operations regularly and has intensive care and bowel-surgery support on hand. It is a fair question to put to any team, and a good team will not be offended by it.
CION is candid about the division of labour. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres, where it is performed and may be billed. Medical oncology — the chemotherapy either side of the operation, and maintenance therapy afterwards — is delivered in-house.
HIPEC is heated chemotherapy washed through the abdominal cavity at the end of a debulking operation. A randomised trial reported improved outcomes when HIPEC was added at interval debulking specifically, and it is offered selectively in that setting. It is not standard for everyone, it adds to the length and the demands of the operation, and it remains genuinely debated among specialists.
If it is being considered for you, ask what is expected to be gained, what it adds to recovery, and what it costs. Like the surgery it accompanies, HIPEC is delivered at specialist partner centres and coordinated by CION rather than performed in-house.
Expect several days in hospital, longer if bowel surgery was needed, with drains and a catheter for the first part of it. Walking on the first day, breathing exercises and early feeding shorten recovery more than rest does. Pain is managed on a plan rather than on request.
The remaining chemotherapy usually restarts around three to four weeks after the operation, once the wound has healed and blood counts allow. Nutrition matters more here than anywhere else in the pathway: women who eat well recover faster and are less likely to have the next cycle delayed. Dietitian support runs alongside treatment at CION for exactly that reason.
Sometimes the response assessment shows disease that has shrunk, but not enough, or a site that has progressed. That is disappointing and it is not the end of treatment. Chemotherapy usually continues and the resectability question is asked again after further cycles — a delayed debulking operation is a recognised option, not a consolation prize.
Where an operation does not become possible at all, treatment continues with chemotherapy and, where indicated, maintenance therapy. Ovarian cancer responds to systemic treatment better than most cancers, and long periods of good control without an operation do happen. What should never happen is the plan quietly stopping without anyone explaining what replaces it.
Almost everyone arrives with the same unspoken worry: that chemotherapy first is what is offered when surgery is thought pointless. It is worth an unhurried hour to see why that is not the case in your particular scans — or, occasionally, to establish that primary surgery would in fact be the better route for you, and to say so.
Your first consultation at CION is free and runs to about 45 minutes. Bring the CT report and images, the biopsy or cytology result, and any CA-125 values. Much of the useful work is simple: reading the scan with you rather than at you, showing which findings put the surgery second, and agreeing what the response assessment will have to show for the operation to go ahead. Every case is discussed at a tumour board rather than decided by one doctor alone.
We should be clear about the division of care. Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and follow-up. Interval debulking surgery and HIPEC are coordinated with specialist gynaecologic-oncology partner centres, where they are performed and may be billed. That arrangement exists because specialist surgical volume genuinely affects how completely disease is removed, and it is stated upfront rather than left to be discovered later.
Free and unhurried. Long enough to go through the scan that put chemotherapy first, and to answer the question underneath the question.
Medical oncology, imaging and pathology review the sequencing together — including when the surgical window should be reassessed.
Interval debulking with specialist gynaecologic-oncology surgeons at partner centres, performed and billed there. Said plainly, in advance.
Cycles either side of the operation can be given at whichever of our 35+ centres is closest to you, rather than requiring repeat trips into one city hospital.
Most people search for a number within a day of the diagnosis, and most of what they find misleads. Published survival figures for advanced ovarian cancer are historical, so they describe treatment given years ago, before current maintenance therapies existed. They average across substages and across tumour subtypes that behave very differently. Crucially, they mix together women whose surgery removed everything visible and women whose surgery did not — two groups with markedly different outcomes, filed under one heading.
That is the case for not quoting you a percentage for chemotherapy first against surgery first. The trials that compared the two routes found survival no worse with chemotherapy first, which is precisely why the choice can be made on what will give the most complete operation. CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. These are one-year figures across a whole treated population — not cure rates, and not a prediction for any individual.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
One-year survival is not a cure rate and not your personal outlook. Stage, subtype, how completely surgery removes disease, and your general health matter far more to your own prognosis.
*One-year survival rates. CION figures reflect CION’s treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
Because your CT scan, and sometimes a laparoscopic look, suggested that an operation done today would be unlikely to remove every visible deposit of disease. Ovarian cancer spreads across the surface of the abdomen, so it can sit on the diaphragm, on the liver surface or in the mesentery of the small bowel, where complete removal is difficult or unsafe. Chemotherapy given first shrinks those deposits so the same operation can achieve complete removal. Fitness counts too: where someone is unwell from ascites, malnourished, or has significant heart or lung disease, chemotherapy first allows strength to be rebuilt before major surgery. The decision reflects the map of your disease, not a judgement about how treatable it is.
No on both counts. Neoadjuvant chemotherapy is used in advanced disease, so the stage is usually 3 or 4 — but the route itself does not make the outlook worse. Two randomised trials compared operating first with giving chemotherapy first and found survival no worse with chemotherapy first, alongside fewer serious surgical complications. Surgery has not been ruled out; it has been moved to the point where it is most likely to succeed. The one thing worth confirming with your team is that interval debulking surgery is part of the written plan, and that a date will be considered after the response assessment rather than left open-ended.
Usually three, sometimes four, given every three weeks, so roughly nine to twelve weeks of treatment before surgery is considered. After the third cycle a repeat CT scan is compared with the baseline, alongside the CA-125 trend and a clinical examination. If everything visible now looks removable, the operation is booked for around four to six weeks after the last cycle, once blood counts have recovered. If the response is real but incomplete, further cycles are given and the question is asked again. The number is not fixed in advance because it depends on what the scan shows, and a plan that adjusts to the response is working as intended.
Interval debulking is the cytoreductive operation performed between cycles of chemotherapy, usually after the third or fourth. It typically removes both ovaries and fallopian tubes, the uterus, the omentum and any involved peritoneum, with lymph node removal or bowel surgery where required. Success is defined by what remains at the end rather than by how much was taken out: complete cytoreduction, often written R0, means no visible disease left. Outcomes are consistently better when that is achieved, which is why the operation should be done by a surgeon trained in gynaecologic oncology working in a centre that performs these regularly. Ask directly who will be operating and how often they do this procedure.
The plan adjusts rather than stops. If the response assessment shows shrinkage that is real but not yet sufficient, chemotherapy usually continues and resectability is reassessed after further cycles — a delayed debulking operation is a recognised option. If a site has progressed despite treatment, your oncologist will discuss changing the systemic treatment instead. Where an operation does not become possible at all, treatment continues with chemotherapy and, where indicated, maintenance therapy; ovarian cancer responds to systemic treatment better than most cancers, and long periods of good control without surgery do happen. What should always be explained is what replaces the original plan, and what it is aiming for.
HIPEC is heated chemotherapy circulated through the abdominal cavity at the end of a debulking operation. A randomised trial reported better outcomes when it was added at interval debulking specifically, which is why it is offered selectively in that setting rather than to everyone. It lengthens the operation and adds to recovery, and specialists genuinely disagree about how widely it should be used. It is reasonable to ask whether your case is one where it might help, what is expected to be gained, and what it will cost. Like the surgery it accompanies, HIPEC is delivered at specialist partner centres and coordinated by CION rather than performed in-house.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: the chemotherapy either side of the operation and maintenance therapy afterwards, across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and follow-up. Interval debulking surgery and HIPEC are coordinated with specialist gynaecologic-oncology partner centres, where they are performed and may be billed — we state that upfront rather than leave it to be discovered later. Every case is discussed at a tumour board, and costs are set out in writing before treatment starts.